Elizabeth R Wolf1,2, Alicia Richards3, Martin Lavallee3, Roy T Sabo3, Alan R Schroeder4, Matthew Schefft5,2, Alex H Krist6. 1. Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia elizabeth.wolf@vcuhealth.org. 2. Departments of Pediatrics. 3. Biostatistics. 4. Department of Pediatrics, School of Medicine, Stanford University, Palo Alto, California. 5. Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia. 6. Family Medicine and Population Health, Virginia Commonwealth University, Richmond, Virginia.
Abstract
BACKGROUND AND OBJECTIVES: The American Academy of Pediatrics recommends against the routine use of β-agonists, corticosteroids, antibiotics, chest radiographs, and viral testing in bronchiolitis, but use of these modalities continues. Our objective for this study was to determine the patient, provider, and health care system characteristics that are associated with receipt of low-value services. METHODS: Using the Virginia All-Payers Claims Database, we conducted a retrospective cross-sectional study of children aged 0 to 23 months with bronchiolitis (code J21, International Classification of Diseases, 10th Revision) in 2018. We recorded medications within 3 days and chest radiography or viral testing within 1 day of diagnosis. Using Poisson regression, we identified characteristics associated with each type of overuse. RESULTS: Fifty-six percent of children with bronchiolitis received ≥1 form of overuse, including 9% corticosteroids, 17% antibiotics, 20% β-agonists, 26% respiratory syncytial virus testing, and 18% chest radiographs. Commercially insured children were more likely than publicly insured children to receive a low-value service (adjusted prevalence ratio [aPR] 1.21; 95% confidence interval [CI]: 1.15-1.30; P < .0001). Children in emergency settings were more likely to receive a low-value service (aPR 1.24; 95% CI: 1.15-1.33; P < .0001) compared with children in inpatient settings. Children seen in rural locations were more likely than children seen in cities to receive a low-value service (aPR 1.19; 95% CI: 1.11-1.29; P < .0001). CONCLUSIONS: Overuse in bronchiolitis remains common and occurs frequently in emergency and outpatient settings and rural locations. Quality improvement initiatives aimed at reducing overuse should include these clinical environments.
BACKGROUND AND OBJECTIVES: The American Academy of Pediatrics recommends against the routine use of β-agonists, corticosteroids, antibiotics, chest radiographs, and viral testing in bronchiolitis, but use of these modalities continues. Our objective for this study was to determine the patient, provider, and health care system characteristics that are associated with receipt of low-value services. METHODS: Using the Virginia All-Payers Claims Database, we conducted a retrospective cross-sectional study of children aged 0 to 23 months with bronchiolitis (code J21, International Classification of Diseases, 10th Revision) in 2018. We recorded medications within 3 days and chest radiography or viral testing within 1 day of diagnosis. Using Poisson regression, we identified characteristics associated with each type of overuse. RESULTS: Fifty-six percent of children with bronchiolitis received ≥1 form of overuse, including 9% corticosteroids, 17% antibiotics, 20% β-agonists, 26% respiratory syncytial virus testing, and 18% chest radiographs. Commercially insured children were more likely than publicly insured children to receive a low-value service (adjusted prevalence ratio [aPR] 1.21; 95% confidence interval [CI]: 1.15-1.30; P < .0001). Children in emergency settings were more likely to receive a low-value service (aPR 1.24; 95% CI: 1.15-1.33; P < .0001) compared with children in inpatient settings. Children seen in rural locations were more likely than children seen in cities to receive a low-value service (aPR 1.19; 95% CI: 1.11-1.29; P < .0001). CONCLUSIONS: Overuse in bronchiolitis remains common and occurs frequently in emergency and outpatient settings and rural locations. Quality improvement initiatives aimed at reducing overuse should include these clinical environments.
Authors: Suzanne Schuh; Franz E Babl; Stuart R Dalziel; Stephen B Freedman; Charles G Macias; Derek Stephens; Dale W Steele; Ricardo M Fernandes; Roger Zemek; Amy C Plint; Todd A Florin; Mark D Lyttle; David W Johnson; Serge Gouin; David Schnadower; Terry P Klassen; Lalit Bajaj; Javier Benito; Anupam Kharbanda; Nathan Kuppermann Journal: Pediatrics Date: 2017-12 Impact factor: 7.124
Authors: Grant M Mussman; Michele Lossius; Faiza Wasif; Jeffrey Bennett; Kristin A Shadman; Susan C Walley; Lauren Destino; Elizabeth Nichols; Shawn L Ralston Journal: Pediatrics Date: 2018-01-10 Impact factor: 7.124
Authors: Dorothy Damore; Jonathan M Mansbach; Sunday Clark; Maria Ramundo; Carlos A Camargo Journal: Pediatr Emerg Care Date: 2010-10 Impact factor: 1.454
Authors: Louise Elaine Vaz; Kenneth P Kleinman; Matthew D Lakoma; M Maya Dutta-Linn; Chelsea Nahill; James Hellinger; Jonathan A Finkelstein Journal: Pediatrics Date: 2015-07-20 Impact factor: 7.124
Authors: Alan R Schroeder; Jonathan M Mansbach; Michelle Stevenson; Charles G Macias; Erin Stucky Fisher; Besh Barcega; Ashley F Sullivan; Janice A Espinola; Pedro A Piedra; Carlos A Camargo Journal: Pediatrics Date: 2013-10-07 Impact factor: 7.124
Authors: Todd A Florin; Terri Byczkowski; Richard M Ruddy; Joseph J Zorc; Matthew Test; Samir S Shah Journal: J Pediatr Date: 2014-07-09 Impact factor: 4.406
Authors: Katri Korpela; Anne Salonen; Lauri J Virta; Riina A Kekkonen; Kristoffer Forslund; Peer Bork; Willem M de Vos Journal: Nat Commun Date: 2016-01-26 Impact factor: 14.919